

Bevacizumab-Biosimilars Insight, 2022

<https://marketpublishers.com/r/B489208309B7EN.html>

Date: January 2022

Pages: 125

Price: US\$ 2,000.00 (Single User License)

ID: B489208309B7EN

Abstracts

This report can be delivered to the clients within 96-120 hours

DelveInsight's, "Bevacizumab– Biosimilar 2022," report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Bevacizumab Understanding

Bevacizumab: Overview

Bevacizumab, sold under the brand name Avastin, is a medication used to treat a number of types of cancers and a specific eye disease. There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies. In 2004, bevacizumab (Avastin) gained FDA approval for specific types of cancer, and became the first antiangiogenic agent introduced to the market. It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens

which are specific to the type, severity, and stage of cancer.

Bevacizumab Biosimilars: Drugs Chapters

This segment of the Bevacizumab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Bevacizumab Biosimilars: Marketed Drugs

Mvasi: Amgen

Mvasi is a vascular endothelial growth factor inhibitor. The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment of cancer.

Bryxta: Zydus

Bryxta is a recombinant humanized monoclonal antibody (containing 1337 amino acids) produced in Chinese Hamster Ovary cell line. VEGF is a signal protein which stimulates vasculogenesis and angiogenesis. Bevacizumab binds to VEGF and inhibits its interactions with VEGF receptors (VEGFRs), Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. This results in regression of tumour vasculature and inhibition of new tumour vessel growth.

Further product details are provided in the report.....

Bevacizumab Biosimilars: Emerging Drugs

HD204: Prestige BioPharma

Prestige BioPharma is developing HD204 for the treatment of several Solid Tumors. In 2019, Prestige BioPharma announced positive results from a phase I clinical trial (SAMSON-I) evaluating the pharmacokinetics (PK), safety and immunogenicity of

biosimilar candidate HD204 to Avastin (bevacizumab).

GB 222: Genor Biopharma

Genor Biopharma is developing GB 222 for the treatment of Non-small cell lung cancer. The drug is currently in phase III stage of development.

Further product details are provided in the report.....

Bevacizumab: Therapeutic Assessment

This segment of the report provides insights about the different Bevacizumab biosimilars segregated based on following parameters that define the scope of the report, such as:

Major Players in Bevacizumab

There are approx. 40+ key companies which are developing the therapies for Bevacizumab.

Phases

DelveInsight's report covers around 40+ products under different phases of clinical development like

Marketed stage products

Late stage products (BLA Filed and Phase III)

Mid-stage products (Phase II and

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Bevacizumab pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Parenteral

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibodies

Peptide

Protein

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Bevacizumab: Pipeline Development Activities

The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Bevacizumab biosimilars drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bevacizumab biosimilar drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Bevacizumab R&D. The therapies under development are focused on novel approaches to treat/improve Bevacizumab.

In August 2020, Bio-Thera Solutions and BeiGene announced that the companies have executed a license, distribution, and supply agreement for China for Bio-Thera's BAT1706, an investigational biosimilar to Avastin (bevacizumab).

In July 2019, Amgen and Allergan announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab), are now available in the United States (U.S.).

In June 2020, Samsung Bioepis announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for AYBINTIO, a biosimilar candidate referencing Avastin (bevacizumab).

In March 2020, the FDA has accepted a Biologics License Application (BLA) for MYL-1402O, a proposed biosimilar to bevacizumab (Avastin), according to a press release from co-developers Biocon and Mylan. The BLA is seeking approval for the biosimilar as a treatment for multiple types of cancer and the FDA has set an action date goal of December 27, 2020, for a decision on the BLA.

Bevacizumab Biosimilars Report Insights

Bevacizumab Biosimilar Pipeline Analysis

Therapeutic Assessment

Sales Assessment

Unmet Needs

Impact of Drugs

Bevacizumab Biosimilar Report Assessment

Marketed Product profiles

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Sales Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Bevacizumab Biosimilars?

How many Bevacizumab biosimilars are developed by each company?

How many emerging biosimilars are in mid-stage, and late-stage?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bevacizumab biosimilars therapeutics?

What are the clinical studies going on for Bevacizumab biosimilars and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

BioIntegrator

Mycenax Biotech

Biocad

Daiichi Sankyo/ Amgen

Kashiv BioSciences

Harvest Moon Pharmaceuticals

Coherus BioSciences

Celltrion

Centus Biotherapeutics Limited

Shanghai Henlius Biotech

Innovent Biologics

mAbxience S.A

Amgen/ Allergan

Outlook Therapeutics

Pfizer

R-Pharm

Samsung Bioepis

Zhejiang Teruisi Pharmaceutical

Tanvex Biopharma

Pfizer

Zydus Cadila

Reliance Life Sciences

Laboratorio Elea

Biocon/Mylan

Bio-Thera Solutions

BioXpress Therapeutics

Boehringer Ingelheim

Zydus Cadila

Dr Reddy's

mAbxience

Genor Biopharma

Gene Techno Science

Key Products

BI-MAB-02

AiNEX

BCD-021

CHS-5217

CT-16

CT-P16

FKB238

HLX04

IBI-305

MB02

Mvasi

ONS-1045

PF-06439535 (ZIRABEV)

RPH001

SB8

SB9

TRS003

TX-16

Zirabev

Bryxta

BevacRel

Lumiere

KRABEVA

BAT1706

BX 2314

BI 695502

Bryxta

Versavo

Bevax

GB 222

GBS-004

Contents

1. KEY INSIGHTS

2. BEVACIZUMAB BIOSIMILARS: SNAPSHOT

3. EXECUTIVE SUMMARY

3.1. Overview

3.2. The Basics of Biologics.

3.3. Biosimilars are not the Same as Generic Drugs

3.4. Economics of Biosimilars – the Promise of Lower Prices, but at What Cost?

3.5. What Patients Need to Know About Biosimilars

4. REGULATORY OUTLOOK FOR BIOSIMILARS

4.1. North America

4.1.1. US

4.1.2. Canada

4.2. Europe

4.3. Asia Pacific

4.3.1. China

4.3.2. India

4.3.3. Japan

4.3.4. South Korea

4.3.5. Australia

4.4. Rest Of The World

4.4.1. Brazil

4.4.2. Mexico

4.4.3. Argentina

4.4.4. Saudi Arabia

*More Countries would be added in the final report

5. BEVACIZUMAB (REFERENCE PRODUCT: AVASTIN)

5.1. Drug Profile

5.2. Product Overview

5.3. Regulatory Approvals and Launch

5.4. Indications

- 5.5. Mechanism of Action
- 5.6. Dosage and Administration
- 5.7. Dosage and Strengths
- 5.8. Dose Modification
- 5.9. Route of Synthesis
- 5.10. Pharmacology
- 5.11. Pharmacodynamics
- 5.12. Pharmacokinetics
- 5.13. Adverse Reactions
- 5.14. Product Snapshot
- 5.15. Development Milestones

6. RESEARCH AND DEVELOPMENT

- 6.1. Clinical Trials Information
- 6.2. Safety and Efficacy

7. AVASTIN BIOSIMILAR: EMERGING OPPORTUNITIES

8. BEVACIZUMAB: BIOSIMILARS ASSESSMENT

- 8.1. Assessment by Product Type
- 8.2. Assessment by Route of Administration
- 8.3. Assessment by Molecule type
- 8.4. Sales Assessment

9. BEVACIZUMAB BIOSIMILARS PROFILES: BY COMPANY

- 9.1.1. Pfizer
 - 9.1.1.1. PF-06439535: Pfizer
 - 9.1.1.1.1. Product Information
 - 9.1.1.1.2. Research and Development
 - 9.1.1.1.3. Other Development Activities
 - 9.1.1.1.4. General Description Table
- 9.1.2. Amgen
 - 9.1.2.1. Mvasi: Amgen
 - 9.1.2.1.1. Product Information
 - 9.1.2.1.2. Research and Development
 - 9.1.2.1.3. Other Development Activities

9.1.2.1.4. General Description Table

9.1.3. Celltrion

9.1.3.1. CT-P16 : Celltrion

9.1.3.1.1. Product Information

9.1.3.1.2. Research and Development

9.1.3.1.3. Other Development Activities

9.1.3.1.4. General Description Table

9.1.4. Prestige Biopharma

9.1.4.1. HD204 : Prestige Biopharma

9.1.4.1.1. Product Information

9.1.4.1.2. Research and Development

9.1.4.1.3. Other Development Activities

9.1.4.1.4. General Description Table

*More Companies and products would be added in the final report

10. BEVACIZUMAB BIOSIMILARS: COMPARATIVE LANDSCAPE: BY COMPANY

11. BEVACIZUMAB BIOSIMILARS: COMPETITIVE LANDSCAPE

11.1.1. Overview

11.1.2. Market Share Analysis

11.1.3. Competitive Scenario

11.1.3.1. Product Launches and approval

11.1.3.2. Partnerships, Collaborations and Agreements

11.1.3.3. Acquisitions

11.1.3.4. Expansions

11.1.3.5. Patent Expiration of Biologics

*More information would be added in the final report

12. MARKET DRIVERS

13. MARKET BARRIERS

14. SWOT ANALYSIS

15. APPENDIX

15.1. Research Methodology

15.1.1. Coverage

15.1.2. Secondary Research

16. BIBLIOGRAPHY

17. DELVEINSIGHT CAPABILITIES

18. DISCLAIMER

19. ABOUT DELVEINSIGHT

I would like to order

Product name: Bevacizumab-Biosimilars Insight, 2022

Product link: <https://marketpublishers.com/r/B489208309B7EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B489208309B7EN.html>